Ryvu Therapeutics, SA
Krakow,
Poland
TAP Partner
Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology using a proprietary discovery engine platform.
Program Name(s)
Therapy Acceleration Program
Project Title
A phase 2 study of RVU120, a novel CDK8 inhibitor, in genetically defined cohorts of patients with AML and high-risk MDSA phase 2 study of RVU120, a novel CDK8 inhibitor, in combination with venetoclax in patients with AML
A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with low-risk MDS
A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with myelofibrosis
